The firm is a healthcare-focused venture capital firm based in the United States that invests in novel, differentiated therapeutics addressing significant unmet medical needs. The firm makes direct equity investments across the full development spectrum, from preclinical programs through clinical- and commercial-stage companies. The firm participates in Seed and first institutional rounds, later-stage private financings, crossover rounds, and PIPE transactions, with the capacity to invest up to approximately $15M over the life of an investment. The firm can act as a lead, co-lead, or co-investor and invests in both private and public companies.
The firm focuses primarily on therapeutics in oncology, immunology, neurology, and rare diseases, while remaining open to other indications on a selective basis. The firm is stage-agnostic and prioritizes differentiated science, strong biological rationale, and programs with meaningful clinical and commercial potential. The firm seeks opportunities capable of addressing substantial unmet needs and reaching important development, regulatory, or commercial value-inflection milestones.
From a company and management team perspective, the firm prefers experienced leadership teams with strong scientific and drug development expertise. The firm partners closely with scientists, entrepreneurs, and institutional co-investors and provides strategic support through its pharmaceutical and healthcare industry network. The firm seeks to help portfolio companies advance toward clinical milestones, strategic partnerships, follow-on financings, and successful exits.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment